series-a
Stage
1
Investors
About
ProLynx develops an ultra-long-acting drug delivery platform using degradable hydrogel microspheres and tunable linker chemistry to enable extended-release therapeutics for obesity, diabetes, and related metabolic diseases with dosing intervals up to 90 days.
Explore ProLynx's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.